World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 9

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4940)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

232

HTML

2861

Figures (1-2)

444

Sum=3537

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

311

Download

878

Sum=1189

Mar 7, 2024 (publication date) through Mar 18, 2026

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Kong YH, Xu ML, Zhang JJ, Chen GQ, Hong ZH, Zhang H, Dai XX, Ma YF, Zhao XR, Zhang CY, Chen RZ, Xing PF, Zhang LY. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report. World J Gastroenterol 2024; 30(9): 1237-1249 [PMID: 38577174 DOI: 10.3748/wjg.v30.i9.1237]
URL:	https://www.wjgnet.com/1007-9327/full/v30/i9/1237.htm

Number	Citing Articles
1	Jiabao Yang, Xiangrong Zhao, Pengfei Xing, Yuehong Kong, Meiling Xu, Liyuan Zhang. Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies. Cancer Immunology, Immunotherapy 2025; 74(11) doi: 10.1007/s00262-025-04185-y
2	Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments from January to June 2024. World Journal of Gastroenterology 2024; 30(34): 3875-3882 doi: 10.3748/wjg.v30.i34.3875 Abstract(772) \| Core Tip(799) \| Full Article(HTML)(1667) \| Full Article with Cover (PDF)-639K(186) \| Audio-785K(15) \| Peer-Review Report-230K(109) \| Answering Reviewers-209K(118) \| Full Article (PDF)-410K(140) \| Full Article (XML)-117K(115) \| Times Cited (0) \| Total Visits (5818) \| Open
3	Multiple drugs. Reactions Weekly 2024; 2033(1): 208 doi: 10.1007/s40278-024-70318-y
4	Xiangrong Zhao, MengMeng Yang, Junjun Zhang, Yuehong Kong, Meiling Xu, Rongzheng Chen, Qian Yin, Sumeng Wang, Guangqiang Chen, Pengfei Xing, Liyuan Zhang. Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study). Technology in Cancer Research & Treatment 2025; 24 doi: 10.1177/15330338251400412
5	Meiling Xu, Yuehong Kong, Junjun Zhang, Rongzheng Chen, Pengfei Xing, Xiangrong Zhao, Shicheng Li, Yingying Xu, Liyuan Zhang, Li Zou. Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol). Technology in Cancer Research & Treatment 2026; 25 doi: 10.1177/15330338261432537